Gustavo Alencastro Veiga Cruzeiro

Gustavo Alencastro Veiga Cruzeiro

Auto-generated profile, based on publicly available information

Gustavo Alencastro Veiga Cruzeiro

Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2019 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
KSKarina Bezerra Salomão
Karina Bezerra Salomão
CJCarlos Alberto Oliveira de Biagi Junior
Carlos Alberto Oliveira de Biagi Junior
MBMartin Baumgartner
Martin Baumgartner
DSDominik Sturm
Dominik Sturm
Elvis Terci ValeraElvis Terci Valera
Elvis Terci Valera
Next-generation sequencing platforms are routinely used for molecular assignment due to their high impact for risk stratification and prognosis in medulloblastomas. Yet, low and middle-income countries still lack an accurate cost-effective platform to perform this allocation. TaqMan Low Density array (TLDA) assay was performed using a set of 20 genes in 92 medulloblastoma samples. The same methodology was assessed in silico using microarray data for 763 medulloblastoma samples from the GSE85217 study, which performed MB classification by a robust integrative method (Transcriptional, Methylation and cytogenetic profile). Furthermore, we validated in 11 MBs samples our proposed method by Methylation Array 450 K to assess methylation profile along with 390 MB samples (GSE109381) and copy number variations. TLDA with only 20 genes accurately assigned MB samples into WNT, SHH, Group 3 and Group 4 using Pearson distance with the average-linkage algorithm and showed concordance with molecular assignment provided by Methylation Array 450 k. Similarly, we tested this simplified set of gene signatures in 763 MB samples and we were able to recapitulate molecular assignment with an accuracy of 99.1% (SHH), 94.29% (WNT), 92.36% (Group 3) and 95.40% (Group 4), against 97.31, 97.14, 88.89 and 97.24% (respectively) with the Ward.D2 algorithm. t-SNE analysis revealed a high level of concordance (k = 4) with minor overlapping features between Group 3 and Group 4. Finally, we condensed the number of genes to 6 without significantly losing accuracy in classifying samples into SHH, WNT and non-SHH/non-WNT subgroups. Additionally, we found a relatively high frequency of WNT subgroup in our cohort, which requires further epidemiological studies. TLDA is a rapid, simple and cost-effective assay for classifying MB in low/middle income countries. A simplified method using six genes and restricting the final stratification into SHH, WNT and non-SHH/non-WNT appears to be a very interesting approach for rapid clinical decision-making.

16 July 2019 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
TMTaciani de Almeida Magalhães
Taciani de Almeida Magalhães
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
GSGraziella Sousa
Graziella Sousa
KSKeteryne Rodrigues da Silva
Keteryne Rodrigues da Silva
RLRégia Caroline Peixoto Lira
Régia Caroline Peixoto Lira
KBKleiton Silva Borges
Kleiton Silva Borges

22 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PKPaulo Henrique dos Santos Klinger
Paulo Henrique dos Santos Klinger
LDLara Elis Alberici Delsin
Lara Elis Alberici Delsin
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
AAAugusto Faria Andrade
Augusto Faria Andrade
Régia Caroline Caroline Peixoto LiraRégia Caroline Caroline Peixoto Lira
Régia Caroline Caroline Peixoto Lira
Elvis Terci ValeraElvis Terci Valera
Elvis Terci Valera
We evaluated the potential effects of ATO in different pediatric SHH-MB cell lines (ONS-76: TP53-wild type; DAOY and UW402: TP53-mutated). MB cell lines molecular subgroup was confirmed and TP53 mutations were validated. Cell viability, clonogenicity and apoptosis were evaluated after ATO treatment at different concentrations (1–16 µM) alone or combined with irradiation doses (0.5, 1, 2 and 4 Gy). Rad51 and Ku86 proteins were evaluated by WB. ATO treatment reduced cell viability for all SHH-MB cell lines. Significant decrease of clonogenic capacity and higher apoptosis rates were also observed after ATO exposure, being cell death more pronounced (>70%) for the SHH-MB TP53-mutated. Combined treatment of ATO with irradiation also reduced colonies formation in UW402 tumor cells, which was independent of DNA damage repair proteins Rad51 and Ku86. In silico analyses suggested that a set of genes from cell cycle and p53 pathways are differentially expressed in SHH tumor subtypes, suggesting that cell lines may respond to therapies according to the gene expression profiles. Herein, we showed ATO cytotoxicity in pediatric SHH cell lines, with marked radiosensitizing effect for the MB-SHH TP53-mutated cells. These results highlight the potential of ATO, alone or in combination with radiotherapy, supporting further clinical investigations.

26 March 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
KSKarina Bezerra Salomão
Karina Bezerra Salomão
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
RBRicardo Bonfim-Silva
Ricardo Bonfim-Silva
LGLenisa Geron
Lenisa Geron
FRFernando Silva Ramalho
Fernando Silva Ramalho
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone

31 May 2022 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TMTaciani de Almeida Magalhães
Taciani de Almeida Magalhães
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
GSGraziella Ribeiro de Sousa
Graziella Ribeiro de Sousa
BEBernhard Englinger
Bernhard Englinger
LNLuis Fernando Peinado Nagano
Luis Fernando Peinado Nagano
Elvis Terci ValeraElvis Terci Valera
Elvis Terci Valera
Background: Supratentorial RELA fusion (ST-RELA) ependymomas (EPNs) are resistant tumors without an approved chemotherapeutic treatment. Unfortunately, the molecular mechanisms that lead to chemoresistance traits of ST-RELA remain elusive. The aim of this study was to assess RELA fusion-dependent signaling modules, specifically the role of the Hedgehog (Hh) pathway as a novel targetable vulnerability in ST-RELA. Methods: Gene expression was analyzed in EPN from patient cohorts, by microarray, RNA-seq, qRT-PCR, and scRNA-seq. Inhibitors against Smoothened (SMO) (Sonidegib) and Aurora kinase A (AURKA) (Alisertib) were evaluated. Protein expression, primary cilia formation, and drug effects were assessed by immunoblot, immunofluorescence, and immunohistochemistry. Results: Hh components were selectively overexpressed in EPNs induced by the RELA fusion. Single-cell analysis showed that the Hh signature was primarily confined to undifferentiated, stem-like cell subpopulations. Sonidegib exhibited potent growth-inhibitory effects on ST-RELA cells, suggesting a key role in active Hh signaling; importantly, the effect of Sonidegib was reversed by primary cilia loss. We, thus, tested the effect of AURKA inhibition by Alisertib, to induce cilia stabilization/reassembly. Strikingly, Alisertib rescued ciliogenesis and synergized with Sonidegib in killing ST-RELA cells. Using a xenograft model, we show that cilia loss is a mechanism for acquiring resistance to the inhibitory effect of Sonidegib. However, Alisertib fails to rescue cilia and highlights the need for other strategies to promote cilia reassembly, for treating ST-RELA tumors. Conclusion: Our study reveals a crucial role for the Hh pathway in ST-RELA tumor growth, and suggests that rescue of primary cilia represents a vulnerability of the ST-RELA EPNs.

1 March 2021 in Neurochemistry International
Verified
Journal Article
Closed access
GCGustavo Alencastro Veiga Cruzeiro
Gustavo Alencastro Veiga Cruzeiro
CRChristopher Rota
Christopher Rota
OHOlivia A. Hack
Olivia A. Hack
RSRosalind Segal
Rosalind Segal
MFMariella G. Filbin
Mariella G. Filbin